Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis

被引：0

作者：

Schneider, Udo ^{[1
]}

Siegert, Elise ^{[1
,2
]}

Glaser, Sven ^{[3
,4
]}

Kruger, Klaus ^{[5
]}

Krause, Andreas ^{[6
]}

机构：

[1] Charite Univ Med Berlin, Med Klin Schwerpunkt Rheumatol & Klin Immunol, Charitepl 1, D-10117 Berlin, Germany

[2] Berlin Inst Hlth, Berlin, Germany

[3] Vivantes Klinikum Neukolln, Klin Innere Med Pneumol & Infektiol, Berlin, Germany

[4] Vivantes Klinikum Spandau, Klin Innere Med Pneumol, Berlin, Germany

[5] Rheumatol Praxiszentrum, Munich, Germany

[6] Immanuel Krankenhaus Berlin, Innere Med Klin, Abt Rheumatol Klin Immunol & Osteol, Berlin, Germany

来源：

ZEITSCHRIFT FUR RHEUMATOLOGIE | 2021年 / 80卷 / 09期

关键词：

Immunosuppression; Cyclophosphamide; Tocilizumab; Nintedanib; SSc-ILD; STEM-CELL TRANSPLANTATION; DOUBLE-BLIND; PULSE CYCLOPHOSPHAMIDE; SCLERODERMA LUNG; PLACEBO; CORTICOSTEROIDS; AZATHIOPRINE; TOCILIZUMAB; EFFICACY; PHASE-2;

D O I：

10.1007/s00393-021-01088-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Interstitial lung disease in systemic sclerosis (SSc-ILD) is a frequent organ complication with considerable mortality. Therapeutically, immunosuppressants are primarily used, particularly cyclophosphamide (CYC) and mycophenolate mofetil (MMF). Recently acquired data also showed an efficacy of the biologics rituximab and tocilizumab. The therapeutic options have most recently been expanded by the approval of the antifibrotic drug nintedanib. It is particularly beneficial in progressive fibrosing courses of ILD despite immunosuppression. The data from controlled trials on the efficacy and safety of CYC and MMF compiled in this review argue for a preferential use of MMF; however, the approval of MMF for this indication is still lacking. This is urgently needed for improved and simplified care of patients with SSc-ILD.

引用

页码：868 / 878

页数：11

共 42 条

[1] Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria [J].

Andreasson, K. ;

Saxne, T. ;

Bergknut, C. ;

Hesselstrand, R. ;

Englund, M. .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (10) :1788-1792

[2] Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome [J].

Bouros, D ;

Wells, AU ;

Nicholson, AG ;

Colby, TV ;

Polychronopoulos, V ;

Pantelidis, P ;

Haslam, PL ;

Vassilakis, DA ;

Black, CM ;

du Bois, RM .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (12) :1581-1586

[3] Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial [J].

Burt, Richard K. ;

Shah, Sanjiv J. ;

Dill, Karin ;

Grant, Thomas ;

Gheorghiade, Mihai ;

Schroeder, James ;

Craig, Robert ;

Hirano, Ikuo ;

Marshall, Karin ;

Ruderman, Eric ;

Jovanovic, Borko ;

Milanetti, Francesca ;

Jain, Sandeep ;

Boyce, Kristin ;

Morgan, Amy ;

Carr, James ;

Barr, Walter .

LANCET, 2011, 378 (9790) :498-506

[4] BSR and BHPR guideline for the treatment of systemic sclerosis [J].

Denton, Christopher P. ;

Hughes, Michael ;

Gak, Nataliya ;

Vila, Josephine ;

Buch, Maya H. ;

Chakravarty, Kuntal ;

Fligelstone, Kim ;

Gompels, Luke L. ;

Griffiths, Bridget ;

Herrick, Ariane L. ;

Pang, Jay ;

Parker, Louise ;

Redmond, Anthony ;

van Laar, Jacob ;

Warburton, Louise ;

Ong, Voon H. .

RHEUMATOLOGY, 2016, 55 (10) :1906-1910

[5] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease [J].

Distler, Oliver ;

Highland, Kristin B. ;

Gahlemann, Martina ;

Azuma, Arata ;

Fischer, Aryeh ;

Mayes, Maureen D. ;

Raghu, Ganesh ;

Sauter, Wiebke ;

Girard, Mannaig ;

Alves, Margarida ;

Clerisme-Beaty, Emmanuelle ;

Stowasser, Susanne ;

Tetzlaff, Kay ;

Kuwana, Masataka ;

Maher, Toby M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26) :2518-2528

[6] Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial [J].

Ebata, Satoshi ;

Yoshizaki, Ayumi ;

Oba, Koji ;

Kashiwabara, Kosuke ;

Ueda, Keiko ;

Uemura, Yukari ;

Watadani, Takeyuki ;

Fukasawa, Takemichi ;

Miura, Shunsuke ;

Yoshizaki-Ogawa, Asako ;

Asano, Yoshihide ;

Okiyama, Naoko ;

Kodera, Masanari ;

Hasegawa, Minoru ;

Sato, Shinichi .

LANCET RHEUMATOLOGY, 2021, 3 (07) :E489-E497

[7] Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study [J].

Elhai, Muriel ;

Boubaya, Marouane ;

Distler, Oliver ;

Smith, Vanessa ;

Matucci-Cerinic, Marco ;

Alegre Sancho, Juan Jose ;

Truchetet, Marie-Elise ;

Braun-Moscovici, Yolanda ;

Iannone, Florenzo ;

Novikov, Pavel I. ;

Lescoat, Alain ;

Siegert, Elise ;

Castellvi, Ivan ;

Airo, Paolo ;

Vettori, Serena ;

De Langhe, Ellen ;

Hachulla, Eric ;

Erler, Anne ;

Ananieva, Lidia ;

Krusche, Martin ;

Lopez-Longo, F. J. ;

Distler, Joerg H. W. ;

Hunzelmann, Nicolas ;

Hoffmann-Vold, Anna-Maria ;

Riccieri, Valeria ;

Hsu, Vivien M. ;

Pozzi, Maria R. ;

Ancuta, Codrina ;

Rosato, Edoardo ;

Mihai, Carina ;

Kuwana, Masataka ;

Saketkoo, Lesley Ann ;

Chizzolini, Carlo ;

Hesselstrand, Roger ;

Ullman, Susanne ;

Yavuz, Sule ;

Rednic, Simona ;

Caimmi, Cristian ;

Bloch-Queyrat, Coralie ;

Allanore, Yannick ;

Guiducci, Serena ;

Walker, Ulrich A. ;

Kyburz, Diego ;

Lapadula, Giovanni ;

Maurer, Britta ;

Jordan, Suzana ;

Dobrota, Rucsandra ;

Becvar, Radim ;

Sierakowsky, Stanislaw ;

Bielecka, Otylia Kowal .

ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (07) :979-987

[8] 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [J].

Fanouriakis, Antonis ;

Kostopoulou, Myrto ;

Cheema, Kim ;

Anders, Hans-Joachim ;

Aringer, Martin ;

Bajema, Ingeborg ;

Boletis, John ;

Frangou, Eleni ;

Houssiau, Frederic A. ;

Hollis, Jane ;

Karras, Adexandre ;

Marchiori, Francesca ;

Marks, Stephen D. ;

Moroni, Gabriella ;

Mosca, Marta ;

Parodis, Ioannis ;

Praga, Manuel ;

Schneider, Matthias ;

Smolen, Josef S. ;

Tesar, Vladimir ;

Trachana, Maria ;

van Vollenhoven, Ronald F. ;

Voskuyl, Alexandre E. ;

Teng, Y. K. Onno ;

van Leew, Bernadette ;

Bertsias, George ;

Jayne, David ;

Boumpas, Dimitrios T. .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (06) :713-723

[9] Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners [J].

Farge, D. ;

Burt, R. K. ;

Oliveira, M-C ;

Mousseaux, E. ;

Rovira, M. ;

Marjanovic, Z. ;

de Vries-Bouwstra, J. ;

Del Papa, N. ;

Saccardi, R. ;

Shah, S. J. ;

Lee, D. C. ;

Denton, C. ;

Alexander, T. ;

Kiely, D. G. ;

Snowden, J. A. .

BONE MARROW TRANSPLANTATION, 2017, 52 (11) :1495-1503

[10] Treatment Algorithms for Systemic Sclerosis According to Experts [J].

Fernandez-Codina, Andreu ;

Walker, Kyle M. ;

Pope, Janet E. .

ARTHRITIS & RHEUMATOLOGY, 2018, 70 (11) :1820-1828

← 1 2 3 4 5 →